These favorable characteristics of the EVs and Nbs strengthen our hypothesis that EVs can be bioengineered to express Trop2-specific nanobodies, allowing for a more targeted antitumor therapy for breast cancer. This evidence concerns the gene TACSTD2 and breast carcinoma.